Mechanistic Insight from Preclinical Models of Parkinson’s Disease Could Help Redirect Clinical Trial Efforts in GDNF Therapy

Código QR

Mechanistic Insight from Preclinical Models of Parkinson’s Disease Could Help Redirect Clinical Trial Efforts in GDNF Therapy

Parkinson’s disease (PD) is characterized by four pathognomonic hallmarks: (1) motor and non-motor deficits; (2) neuroinflammation and oxidative stress; (3) pathological aggregates of the α-synuclein (α-syn) protein; (4) neurodegeneration of the nigrostriatal system. Recent evidence sustains that th...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Karen M. Delgado-Minjares, Daniel Martinez-Fong, Irma A. Martínez-Dávila, Cecilia Bañuelos, M. E. Gutierrez-Castillo, Víctor Manuel Blanco-Alvarez, Maria-del-Carmen Cardenas-Aguayo, José Luna-Muñoz, Mar Pacheco-Herrero, Luis O. Soto-Rojas
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	neurodegenerative diseases α-synuclein neuroinflammation neurotrophic factors anti-α-synuclein therapy anti-inflammatory therapy Biology (General) QH301-705.5 Chemistry QD1-999
Acceso en línea:	https://doaj.org/article/d402cb1c3197411e954425395eecb767
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

CK1BP Reduces α-Synuclein Oligomerization and Aggregation Independent of Serine 129 Phosphorylation
por: Lea Elsholz, et al.
Publicado: (2021)

Peptide-Based Vaccines for Neurodegenerative Diseases: Recent Endeavors and Future Perspectives
por: Vyronia Vassilakopoulou, et al.
Publicado: (2021)

Alpha-Synuclein, cyclooxygenase-2 and prostaglandins-EP2 receptors as neuroinflammatory biomarkers of autism spectrum disorders: Use of combined ROC curves to increase their diagnostic values
por: Afaf El-Ansary, et al.
Publicado: (2021)

Investigation of the effects of carbon-based nanomaterials on A53T alpha-synuclein aggregation using a whole-cell recombinant biosensor
por: Mohammadi S, et al.
Publicado: (2017)

α-synuclein interaction with zero-valent iron nanoparticles accelerates structural rearrangement into amyloid-susceptible structure with increased cytotoxic tendency
por: Tahaei Gilan SS, et al.
Publicado: (2019)

Dl-3-n-Butylphthalide Rescues Dopaminergic Neurons in Parkinson’s Disease Models by Inhibiting the NLRP3 Inflammasome and Ameliorating Mitochondrial Impairment
por: Rongfang Que, et al.
Publicado: (2021)

Graphene-Based Nanoparticles as Potential Treatment Options for Parkinson’s Disease: A Molecular Dynamics Study
por: Alimohammadi E, et al.
Publicado: (2020)

Effect of superparamagnetic nanoparticles coated with various electric charges on α-synuclein and β-amyloid proteins fibrillation process
por: Javdani N, et al.
Publicado: (2019)

Molecular chaperones and Parkinson's disease
por: Shenglan Hu, et al.
Publicado: (2021)

Alpha-Synuclein Induced Immune Cells Activation and Associated Therapy in Parkinson’s Disease
por: Ruichen Su, et al.
Publicado: (2021)

Inhibition of LRRK2 kinase activity promotes anterograde axonal transport and presynaptic targeting of α-synuclein
por: Charlotte F. Brzozowski, et al.
Publicado: (2021)

Assembly of α-synuclein and neurodegeneration in the central nervous system of heterozygous M83 mice following the peripheral administration of α-synuclein seeds
por: Jennifer A. Macdonald, et al.
Publicado: (2021)

Commentary: Dopamine-Dependent Early Synaptic and Motor Dysfunctions Induced by α-Synuclein in the Nigrostriatal Circuit
por: Jiahui Zhang, et al.
Publicado: (2021)

Association between Sleep, Alzheimer’s, and Parkinson’s Disease
por: Sumire Matsumoto, et al.
Publicado: (2021)

The Small Molecule Alpha-Synuclein Aggregator, FN075, Enhances Alpha-Synuclein Pathology in Subclinical AAV Rat Models
por: Rachel Kelly, et al.
Publicado: (2021)

ABBV-0805, a novel antibody selective for soluble aggregated α-synuclein, prolongs lifespan and prevents buildup of α-synuclein pathology in mouse models of Parkinson's disease
por: Eva Nordström, et al.
Publicado: (2021)

Assessing Plasma Levels of α-Synuclein and Neurofilament Light Chain by Different Blood Preparation Methods
por: Kuo-Hsuan Chang, et al.
Publicado: (2021)

CMV Infection: A Clinical Challenge in Biological Therapy? The Case of Asymptomatic Patients with Persistent Positive Immunoglobulin M Anti-CMV Treated with Secukinumab
por: Gambardella A, et al.
Publicado: (2020)

Tyrosine 136 phosphorylation of α-synuclein aggregates in the Lewy body dementia brain: involvement of serine 129 phosphorylation by casein kinase 2
por: Kazunori Sano, et al.
Publicado: (2021)

Effects of the Toxic Metals Arsenite and Cadmium on α-Synuclein Aggregation In Vitro and in Cells
por: Emma Lorentzon, et al.
Publicado: (2021)

COMPARISON EFFECT BETWEEN PEGAGAN (Centella asiatica) EXTRACT AND PRAMIPEXOLE TOWARD LOCOMOTOR ACTIVITIES, α - SYNUCLEIN, AND NRF2 EXPRESSION IN ZEBRAFISH PARKINSON MODEL
por: Ayu Trisnawati, et al.
Publicado: (2019)

TLR2 and TLR4 in Parkinson’s disease pathogenesis: the environment takes a toll on the gut
por: Anastazja M. Gorecki, et al.
Publicado: (2021)

Sgt1 Regulates α-Synuclein Subcellular Localization and Expression of Parkinson’s Disease Related Genes, <i>PINK1</i> and <i>PARK9</i>
por: Anastasiia Bohush, et al.
Publicado: (2021)

(De)stabilization of Alpha-Synuclein Fibrillary Aggregation by Charged and Uncharged Surfactants
por: Joana Angélica Loureiro, et al.
Publicado: (2021)

Phosphorylation of Tau and α-Synuclein Induced Neurodegeneration in MPTP Mouse Model of Parkinson’s Disease
por: Hu S, et al.
Publicado: (2020)

Paradoxical SAPHO syndrome observed during anti-TNF-α therapy for Crohn's disease
por: Amano H, et al.
Publicado: (2017)

The ratio and interaction between neurotrophin and immune signaling during electroconvulsive therapy in late-life depression
por: Dore Loef, et al.
Publicado: (2021)

Kaempferol Has Potent Protective and Antifibrillogenic Effects for α-Synuclein Neurotoxicity In Vitro
por: Masatoshi Inden, et al.
Publicado: (2021)

Revisit the Cellular Transmission and Emerging Techniques in Understanding the Mechanisms of Proteinopathies
por: Jinwen Jiang, et al.
Publicado: (2021)

Neuroprotective Effects and Related Mechanisms of Echinacoside in MPTP-Induced PD Mice
por: Zhang ZN, et al.
Publicado: (2021)

Anti-Aggregative Effect of the Antioxidant DJ-1 on the TPPP/p25-Derived Pathological Associations of Alpha-Synuclein
por: Judit Oláh, et al.
Publicado: (2021)

Mechanism of Autophagy Regulation in MPTP-Induced PD Mice via the mTOR Signaling Pathway by Echinacoside
por: Zhang ZN, et al.
Publicado: (2021)

Missense Mutations Modify the Conformational Ensemble of the α-Synuclein Monomer Which Exhibits a Two-Phase Characteristic
por: Adrien Guzzo, et al.
Publicado: (2021)

An overview of the biological disease modifying drugs available for arthritic conditions in South Africa
por: Leonie Harmse, et al.
Publicado: (2016)

LRRK2 inhibitors and their potential in the treatment of Parkinson’s disease: current perspectives
por: Atashrazm F, et al.
Publicado: (2016)

Evaluation of α-synuclein and apolipoprotein E as potential biomarkers in cerebrospinal fluid to monitor pharmacotherapeutic efficacy in dopamine dictated disease states of Parkinson’s disease and schizophrenia
por: Gupta AK, et al.
Publicado: (2019)

Comparative Analysis of Biological Activity of Artificial and Wild Agarwood
por: Sheng Ma, et al.
Publicado: (2021)

EXPRESSION PATTERNS OF CHEMOKINE RECEPTORS CXCR3 AND CCR6, AND THEIR LIGANDS IN PERIPHERAL BLOOD OF PATIENTS WITH CHRONIC HEPATITIS C DURING ANTIVIRAL THERAPY USING PEGYLATED INTERFERONS
por: V. V. Basina, et al.
Publicado: (2019)

Infliximab in Combination with Low-Dose Acitretin in Generalized Pustular Psoriasis: A Report of Two Cases and Review of the Literature
por: Kołt-Kamińska M, et al.
Publicado: (2021)

Management of chronic ocular sarcoidosis: challenges and solutions
por: Matsou A, et al.
Publicado: (2018)